Gt biopharma reports fourth quarter and full-year 2022 financial results and provides corporate update

Brisbane, california, march 30, 2023 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced fourth quarter and full-year 2022 results for the period ended december 31, 2022.
GTBP Ratings Summary
GTBP Quant Ranking